IP Library Granted Patent US 10,184,121
Granted Patent B2
US 10,184,121 · App. 14/744,447 · Granted Jan 22, 2019

Methods for removing viral contaminants from pancreatic extracts

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,184,121
App. No.
14/744,447
Granted
Jan 22, 2019
Kind
B2
Abstract

Methods for screening pancrelipase for RNA virus contamination comprise removing free viral RNA from the pancrelipase, denaturing any viruses in the pancrelipase to release encapsidated RNA into the pancrelipase milieu, and detecting this released RNA. Removal of free viral RNA may comprise treating pancrelipase with RNase and DNase or precipitating the protein fraction of pancrelipase with a salt that precipitates the protein fraction while leaving nucleic acids such as RNA in solution. Pancrelipase substantially devoid of free nucleic acid is also provided.

Claims (7)

1. A method for detecting Hepatitis E virus contamination in a sample comprising pancrelipase, the method comprising (a) treating the sample with a ribonuclease to catalyze degradation of substantially all free RNA in the sample comprising pancrelipase, (b) treating the sample with a ribonuclease inhibitor, (c) treating the sample with an agent to denature capsid of Hepatitis E virus, and (d) amplifying with PCR and detecting encapsidated Hepatitis E virus RNA, wherein the method reduces false positive results of Hepatitis E viral contamination in the sample.

2. The method of claim 1 , optionally comprising extracting the encapsidated Hepatitis E virus RNA and amplifying the extracted Hepatitis E virus RNA.

3. The method of claim 1 , further comprising treating the pancrelipase with a protease inhibitor.

4. The method of claim 1 , wherein the ribonuclease is ribonuclease A.

5. The method of claim 1 , wherein the sample of step a) further comprises free RNA and encapsidated Hepatitis E virus.

6. The method of claim 1 , wherein the ribonuclease inhibitor comprises 1,4-dithiothreitol (DTT).

7. The method of claim 1 , wherein b) further comprises heating pancrelipase and removing a cellular debris via centrifugation or molecular filters.

Assignments (2)
CHANGE OF NAME Recorded Mar 18, 2016
From: APTALIS PHARMA LIMITED
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 038177/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2015
From: ORTENZI, GIOVANNI; GHIDORSI, LUIGI
To: APTALIS PHARMA LTD.
Reel/Frame 036016/0415 →